This is a preview of subscription content, log in via an institution to check access.
Notes
incremental cost-effectiveness ratio
Reference
Eriksson J, et al. Cost-Effectiveness of Biologic Versus Conventional Combination Treatment in Early Rheumatoid Arthritis: 2-Year Results of the Randomised Controlled Swefot Trial. 14th Annual Congress of the European League Against Rheumatism : abstr. OP0094, 12 Jun 2013.
Rights and permissions
About this article
Cite this article
Infliximab therapy painful for costs. PharmacoEcon Outcomes News 683, 8 (2013). https://doi.org/10.1007/s40274-013-0576-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0576-2